Launches are won in the plumbing, and this earnings season shows it
From Liquidia to Tonix to Autolus, the quarter's strongest numbers came from access, shipments and manufacturing execution, not from the label alone.
The label gets you a launch. The plumbing gets you a business.
Read this batch of third-quarter results for what changed rather than what was approved, and a pattern emerges. The companies posting the most convincing numbers are the ones that have turned a product into a working operating system. That means access agreements, patient shipments and manufacturing throughput. CompePharma's view is that this is now the main differentiator among commercial-stage biopharma, and that too many leadership teams still treat it as the work that follows the science rather than part of it.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Reimbursement, not approval, is the commercial gate, and leaders should plan accordingly
This month's payer decisions from CMS, China's NRDL and Medicare show that price and access are set by policy calendars. Companies that treat them as afterthoughts will pay for it.
Show your working: launch revenue is the lagging indicator, and this season proves it
Headline growth rates from small launches are easy to produce and hard to compare. The results that persuade pair revenue with evidence of demand and a plan the economics can fund.
Gross margin is the number that turns a launch into a business
Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.